H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on KMDA stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Andrew Fein’s rating is based on Kamada’s robust growth trajectory, which is driven by its expansion outside the U.S. and increased demand for its products. The company’s revenue of $44 million and adjusted EBITDA of $11.6 million highlight its consistent growth. Key factors contributing to this growth include the strong demand for Glassia in international markets, which addresses unmet needs in the Alpha-1 Antitrypsin Deficiency (AATD) space, and the high sales of Kamrab, supported by a significant contract in Latin America and its critical role in rabies treatment.
Additionally, Kamada’s strategic initiatives are expected to drive future success. The company is focusing on expanding sales in ex-U.S. markets, strengthening its biosimilar portfolio, and enhancing its plasma collection operations. Potential acquisitions and the development of an inhaled AAT program, despite its high risk, are also seen as opportunities for growth. These factors, combined with the company’s efforts to address enrollment challenges in its clinical trials, contribute to Fein’s optimistic outlook and Buy rating for Kamada.
Fein covers the Healthcare sector, focusing on stocks such as Insmed, Neurocrine, and Wave Life Sciences. According to TipRanks, Fein has an average return of -2.0% and a 38.95% success rate on recommended stocks.
In another report released yesterday, Benchmark Co. also maintained a Buy rating on the stock with a $15.00 price target.